Trejo-Ulibarri HM, Solís-S JC

Language: Spanish
References: 18
Page: 163-169
PDF size: 544.24 Kb.

ABSTRACT

To date in Mexico, there are no epidemiological studies on the prevalence and incidence of Parkinson's disease. There are also no studies of a multicentric nature and with sufficient sample size to develop a demographic and clinical profile of subjects with Parkinson's in the country. However, in our country, a prevalence has been estimated between 40 to 50 cases per 100,000 inhabitants/year. Current evidence suggests clinical heterogeneity in populations of different countries. In this review, we present the etiological, physiopathogenic and clinical aspects and the existing association with some biochemical markers of this multifaceted disease.

REFERENCES

1. Consejo de Salubridad General. Diagnóstico y tratamiento de la enfermedad de parkinson inicial y avanzada en el tercer nivel de atención. Guía práctica clínica, México Secretaría de Salubridad 2010; www.cenetec.salud.gob.mx/interior/gpc.html

2. Cervantes-Arriaga A, Rodríguez-Violante M, López-Ruiz M, et al. Caracterización de la enfermedad de Parkinson en México: estudio ReMePARK. Gaceta Médica de México. 2013; 149:497-501.

3. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015; http://dx.doi.org/10.1016/S0140-6736(14)61393-3

4. Wider C, Ross OA, Wszolek ZK. Genetics of Parkinson disease and essential tremor. Curr Opin Neurol. 2010; 23(4):388-93

5. Jenner P, Morris HR, Robbins TW, et al. Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. J Park Dis. 2013;3(1):1-11.

6. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. agosto de 2013;136(8):2419-31.

7. Dias V, Junn E, Mouradian MM. The Role of Oxidative Stress in Parkinson's Disease. J Park Dis. 2013;3(4):461-91.

8. Latourelle JC, Pankratz N, Dumitriu A, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 22 de septiembre de 2009;10:98.

9. Kulisevsky, J., Luquin, M.R., Arbelo, et al. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I). Neurología 28, 503–521. doi:10.1016/j.nrl.2013.05.001

10. Stefanis, L., 2012. α-Synuclein in Parkinson's Disease. Cold Spring Harb. Perspect. Med. 2. doi:10.1101/cshperspect.a009399

11. Lin, X., Cook, T.J., Zabetian, C.P, et al. 2012. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci. Rep. 2. doi:10.1038/srep00954

12. Chen-Plotkin, A.S., Hu, W.T., Siderowf, A, et al. 2011. Plasma EGF levels predict cognitive decline in Parkinson's Disease. Ann. Neurol. 69, 655–663. doi:10.1002/ana.22271

13. Chahine L, Stern M, Chen-Plotkin A. Blood-Based Biomarkers for Parkinson's Disease. Parkinsonism Relat Disord. enero de 2014;20(0 1):S99-103.

14. Mhyre TR, et al. “Parkinson's Disease,” Sub-Cellular Biochemistry 65 (2012): 389–455, doi:10.1007/978-94- 007-5416-4_16.

15. Wu Y-R, Feng I-H, Lyu R-K, et al. 2007. Tumor Necrosis Factor-a Promoter Polymorphism is Associated With the Risk of Parkinson's Disease. Am J Med Genet Part B 144B:300–304.

16. Melissa K McCoy and Malú G Tansey, “TNF Signaling Inhibition in the CNS: Implications for Normal Brain Function and Neurodegenerative Disease,” Journal of Neuro inflammation 5(October 17, 2008): 45, doi:10.1186/1742-2094-5-45.

17. Schapira AHV. Recent developments in biomarkers in Parkinson disease. Cur r Opin Neurol. agosto de 2013;26(4):395-400.

18. Natália Pessoa Rocha, Aline Silva de Miranda, and Antônio Lúcio Teixeira, “Insightsinto Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies,” Bio Med Research International 2015(2015), doi:10.1155/2015/628192.